Retatrutide + Cagrilintide

What it is

The most ambitious combination in the catalog: the compound that copies three hormones at once —the most potent published— together with the amylin analog. Four different satiety and energy expenditure signals in a single vial.

Retatrutide already presses three keys: two that curb hunger and one that increases energy burn. Cagrilintide adds a fourth, amylin, which is independent of the others and prolongs the feeling of fullness. The idea is to cover energy balance from both sides at once: what comes in and what is spent.

What it is used for

• • Research on weight control combining incretins and amylin
• • Energy expenditure and thermogenesis, the branch contributed by glucagon
• • Satiety targeted through four different signals
• • Body recomposition and fat mass

How it is used

Lyophilized powder with both peptides combined. It is reconstituted with bacteriostatic water, swirled without shaking, and stored between 2 and 8 °C. In the literature the components are administered weekly, always with gradual dose escalation ^[1][2].

What has been observed

Results described in the published scientific literature. They are not directions for use or health recommendations.

• • Retatrutide achieved a mean weight reduction of 24.2% at 48 weeks in its phase 2 trial, the highest figure published for an incretin agonist ^[1]
• • Cagrilintide reached 10.8% as monotherapy in its phase 2, and outperformed daily liraglutide despite being injected once a week ^[2]
• • That amylin and incretins add up is not a hypothesis: the combination of cagrilintide with semaglutide reached 20.4% in phase 3, above each component separately ^[3]
• • For both components, the adverse effects described are mostly digestive, dose-dependent and can be attenuated with slow escalation ^[1][2]

How it works

Retatrutide — GIP / GLP-1 / glucagon triple agonist

It acts simultaneously on all three receptors ^[1]. The GIP and GLP-1 branches reduce intake; the glucagon branch is associated with greater energy expenditure and mobilization of liver fat, and it is what distinguishes it from dual agonists ^[5].

Cagrilintide — amylin analog

A long-acting analog designed to resist degradation ^[4]. It acts on receptors in the area postrema and slows gastric emptying, a pathway independent of incretins ^[2].

The rationale for the combination

Four targets spread across two systems that do not overlap. The precedent of cagrilintide with semaglutide shows that adding amylin to an incretin agonist produces a greater effect than the incretin agonist alone ^[3]; this formulation applies the same rationale to a more potent agonist.

State of the evidence

Solid for each component, nonexistent for the combination. Each of the two peptides has published randomized clinical trials ^[1][2], and the principle of combining amylin with an incretin agonist has been validated in phase 3 with another pair ^[3]. But there is no published study of this specific formulation: it is research material, not a medicine, and its combined profile has not been characterized.

⚠️ Product intended exclusively for research and laboratory use. Not for human or veterinary consumption.

References

1. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med, 2023. PubMed 37366315
2. Lau DCW, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a phase 2 dose-finding trial. Lancet, 2021. PubMed 34798060
3. Garvey WT, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med, 2025. PubMed 40544433
4. Kruse T, et al. Development of Cagrilintide, a Long-Acting Amylin Analogue. J Med Chem, 2021. PubMed 34288673
5. Katsi V, et al. Retatrutide — A Game Changer in Obesity Pharmacotherapy. Biomolecules, 2025. PubMed 40563436